Novel approach shows promise for a blood test

December 22, 2002

HOUSTON - In a pilot study, researchers at The University of Texas M. D. Anderson Cancer Center have designed a new type of blood test that may hold promise for evaluating disease progression in prostate cancer patients.

The findings, to be published in the January issue of the journal Nature Biotechnology, and available online December 23 (www.nature.com/naturebiotechnology), also may offer a new insight into the biology of the disease.

"The information based on this retrospective preliminary analysis may, in the future, be useful for physicians to decide among the many therapeutic options available for prostate cancer patients. As of today, these options are largely dependent on the stage of the disease," says Wadih Arap, M.D., Ph.D., the lead author of the study from the Department of Genitourinary Medical Oncology at M. D. Anderson.

By looking at the patterns of antibodies from cancer patients, the researchers found that reactivity against a protein that is present at high levels in prostate tumors correlated with poor prognosis and advanced disease. "Future studies based on these findings are likely to help us understand the mechanisms of disease progression," says co-author Renata Pasqualini, Ph.D.

In this report, the group led by Arap searched for small protein fragments (peptides) that can be recognized by antibodies found in the serum of prostate cancer patients. These small protein fragments turned out to be part of a tumor antigen called GRP78.

The protein fragments were isolated from a large collection of peptides displayed on the surface of small, virus-like particles (phage). These phage collections were incubated with the antibodies purified from the serum of prostate cancer patients, and then individual particles that bind to disease-associated antibodies were recovered.

The team then used the protein fragments and the corresponding native tumor antigen to screen the blood of 108 prostate cancer patients and 71 healthy, matched volunteers. Reactivity against the protein correlated with advanced disease.

GRP78 is a heat shock or "stress" protein that becomes expressed at high levels when cells are exposed to low concentrations of glucose or oxygen. Emerging research shows that heat shock proteins seem to play a role in signaling the immune system into action. What the researchers do not yet know and are currently investigating is whether or not GRP78 contributes directly to progression of prostate cancer, says Pasqualini.

"This study validates the hypothesis that humoral response can serve as a 'labeling system' of human cancer. The observations may be clinically meaningful because the presence of antibodies against this particular antigen correlated with disease progression and patient survival. The findings will stimulate investigation as to how the humoral immune response to cancer can be used as a method to monitor and understand cancer progression clinically," says co-author Christopher Logothetis, M.D., chairman of the Department of Genitourinary Medical Oncology.

According to Logothetis, if the disease is detected at early stages, prostate cancer can be managed by local treatments such as surgery or radiation. At later stages of progression, prostate cancer commonly spreads into specific sites such as the skeleton. When this happens, treatment options are more limited. Novel tools for biochemically staging disease would help physicians and patients evaluate and select the most appropriate therapeutic approach, says Logothetis.

According to researchers, the long-term purpose of this project is to identify circulating antibodies that can serve as an early warning system based on individual patients' immune response against tumors. These antibodies can be used to discover what protein fragments they are recognizing, and correlate their presence with patterns and speed of disease progression. The researchers at M. D. Anderson have demonstrated that phage display technology is effective in identifying such antibodies.

Before this novel blood test can be used clinically, it needs extensive validation, cautions Arap. Pasqualini adds that this particular "biological read-out" of prostate cancer progression based on the pattern of circulating antibodies in the serum of patients is just one in a series that the investigators are working to develop. "This may be one preliminary step towards the development of better tools to evaluate cancer progression."
-end-
Co-authors of the study include Drs. Paul J. Mintz, Jeri Kim, Kim-Anh Do, Xuemei Wang, Ralph G. Zinner, Massimo Cristofanilli, Marco A. Arap, Waun Ki Hong, Patricia Troncoso, Christopher J. Logothetis, Renata Pasqualini and Wadih Arap.

The research was funded by grants from the National Institutes of Health, the Gilson-Longenbaugh Foundation and CaP CURE.

University of Texas M. D. Anderson Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.